Hormonal therapies and meningioma

Cancer Epidemiology, 03/30/2012

Cea–Soriano L et al. – The results do not support a role for exogenous hormone use by females in meningioma development. The risk in males was only observed with high–dose, short–term therapy.


  • A cohort study was performed to evaluate hormone-related factors associated with meningioma.
  • Patients (12-89years) with a first diagnosis of meningioma (January 1996-June 2008) were identified from The Health Improvement Network UK primary care database and age- and sex-matched to controls (n=10000) from the same cohort.
  • Odds ratios (ORs) were calculated following a nested case control analysis using unconditional logistic regression.


  • In total, 745 patients with meningioma were identified from a study population of 2171287.
  • No significantly increased risk of meningioma was found among female users of oral contraceptives (OR: 1.15; CI: 0.67-1.98), hormone replacement therapy (OR: 0.99; CI: 0.73-1.35) or low-dose cyproterone acetate (CPA; OR: 1.51; CI: 0.33-6.86) compared with non-users.
  • There was a significantly increased risk of meningioma among male users of androgen analogues (OR: 19.09; CI: 2.81-129.74) and among users of high-dose CPA (OR: 6.30; CI: 1.37-28.94) compared with non-users, however there were only three cases currently using these drugs.
  • No significant association was found between meningioma and prostate, breast, or genital cancers.

Print Article Summary Cat 2 CME Report